Boehringer Asks High Court to Weigh US Drug Price Negotiations

Boehringer Ingelheim Pharmaceuticals Inc. is asking the Supreme Court to weigh whether a Biden-era drug price negotiation plan violates the US Constitution, joining other manufacturers in similar requests before the high court.

The petition urges the justices to review a decision from the US Court of Appeals for the Second Circuit that dealt a blow last year to the drugmaker’s challenge against the Medicare Drug Price Negotiation Program.

“The Program’s scope and scale alone make this case worthy of review, as it will affect hundreds of billions of dollars in the U.S. pharmaceutical market and millions of patients,” the company ...